Orgenesis (Orgenesis) EBIT per Share : $-2.73 (TTM As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Orgenesis EBIT per Share?

Orgenesis's EBIT per Share for the three months ended in Dec. 2023 was $-1.36. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.73.

During the past 3 years, the average EBIT per Share Growth Rate was 25.00% per year. During the past 5 years, the average EBIT per Share Growth Rate was 10.00% per year. During the past 10 years, the average EBIT per Share Growth Rate was 2.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Orgenesis's EBIT per Share or its related term are showing as below:

ORGS' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -656.3 Med: -5.7 Max: 39.9
Current: 25

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Orgenesis was 39.90% per year. The lowest was -656.30% per year. And the median was -5.70% per year.

ORGS's 3-Year EBIT Growth Rate is ranked better than
76.63% of 1305 companies
in the Biotechnology industry
Industry Median: 3.2 vs ORGS: 25.00

Orgenesis's EBIT for the three months ended in Dec. 2023 was $-43.95 Mil.

Orgenesis EBIT per Share Historical Data

The historical data trend for Orgenesis's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis EBIT per Share Chart

Orgenesis Annual Data

Trend

Nov14

Nov15

Nov16

Nov17

Nov18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-1.40

-4.48

-0.70

-0.40

-2.15

Orgenesis Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-0.01	-0.86	-0.11	-0.40	-1.36

Orgenesis EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Orgenesis's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-62.278	/	29.008
=	-2.15

Orgenesis's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-43.946	/	32.232
=	-1.36

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.73

Orgenesis (NAS:ORGS) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Orgenesis EBIT per Share Related Terms

Thank you for viewing the detailed overview of Orgenesis's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Orgenesis (Orgenesis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (NAS:ORGS) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

45O:Germany

Address

20271 Goldenrod Lane, Germantown, MD, USA, 20876

Website

https://www.orgenesis.com

Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Morgenesis and Therapies.

Executives

Elliot Maltz	officer: Chief Financial Officer	C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116
Jacob Safier	10 percent owner	C/O THE WOLFSON GROUP, ONE STATE STREET PLAZA 29TH FLOOR, NEW YORK NY 10004
Efrat Assa Kunik	officer: Chief Development Officer	C/O ORGENESIS INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
David Sidransky	director	JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205
Mario Philips	director	C/O ATMI, INC, DANBURY CT 06810
Sarah Ferber	officer: Chief Scientific Officer	17B HAHASKALA STREET, TEL AVIV L3 67890
Guy Yachin	director	7 ORCHARD WAY N, POTOMAC MD 20854
Yaron Adler	director	4 HA'NECHOSHET ST., RAMAT HA'CHAYAL, TEL AVIV L3 69710
Vered Caplan	officer: CEO	20 HA'ETZEL STREET, PO BOX 9118 RAMAT EFAL, KIRYAT ONO L3 55280
Universite Libre De Bruxelles	10 percent owner	AVENUE F, ROOSEVELT, 50, BRUSSELS C9 1050
Olivier Belenger	10 percent owner	DIEWEG, 69, BRUSSELS C9 1070
Ii Sa Theodorus	10 percent owner	ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Sca Theodorus	10 percent owner	ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Denis Bedoret	officer: See Remarks	48, RUE AUGUSTE PICCARD, GOSSELIES C9 6041
Ashish Nanda	director	2301, 23RD FLOOR, TIFFANY TOWERS, CLUSTER W, JLT, DUBAI, UAE, DUBAI C0 4452